Navigation Links
Medinox Announces Clinical Results of Naproxen Prodrug
Date:5/26/2009

SAN DIEGO, May 26 /PRNewswire/ -- Medinox, Inc. (Carlsbad, CA) and its development partner, Logical Therapeutics, Inc. (Waltham, MA) announced the results of a double-blind, randomized, active comparator study of LT-NS001 (formerly MX-1094) vs naproxen, in subjects 45 to 70 years of age. LT-NS001 is a novel, patented NCE prodrug of the popular non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed to significantly reduce the GI safety risks, including the formation of ulcers, associated with naproxen. Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class.

In this study, subjects underwent upper endoscopies at baseline and on day seven. Subjects receiving LT-NS001 experienced statistically significantly fewer endoscopically confirmed gastric ulcers compared to subjects receiving naproxen.

LT-NS001 is pharmacologically inactive as an NSAID in the GI tract, but once absorbed into the blood stream, it is converted rapidly and quantitatively to naproxen. It is being developed to provide therapeutic levels of naproxen while avoiding high local concentrations of naproxen in the GI tract, thereby reducing the local GI toxicity associated with conventional naproxen.

LT-NS001 has been studied in various randomized controlled single-dose and multiple-dose clinical studies. In all cases, there were no serious adverse events and LT-NS001 was well tolerated. Moreover, when the subjects were dosed twice daily with LT-NS001, plasma concentrations of naproxen were within the therapeutic range.

NSAIDs are the most common medications taken worldwide for the treatment of pain, inflammation, fever and arthritics, including both rheumatoid arthritis (RA) and osteoarthritis (OA). The use of NSAIDs is associated with serious side effects, the most frequent being an increased rate of gastric and duodenal ulcers. In the United States alone, the direct costs of treating ulcer complications associated with NSAID use exceed $4 billion a year. Serious NSAID-induced GI complications such as hemorrhage and perforation are directly responsible for about 20,000 deaths per year in the United States.

About Medinox, Inc.

Medinox, based in Carlsbad, CA, is a privately held biotechnology company, focused on developing novel therapeutic drugs for treating inflammation and septic shock. For more information about Medinox and its products, visit the company's website at www.medinox.com., or contact Monte Lai, Ph.D., President & CEO of Medinox, Inc. at cslai@medinox.com.

About Logical Therapeutics, Inc.

Based in Waltham, MA, Logical Therapeutics Inc. is a venture-backed, privately held biotechnology company focused on the development of products that treat diseases associated with inflammation. Logical's investors include SV Life Sciences, Burrill and Company, Novo Ventures A/S and Novitas Capital. For more information on Logical Therapeutics, visit the company's website at www.logicaltherapeutics.com.


'/>"/>
SOURCE Medinox, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Healthy Rebates, Inc. Announces the Launch of My HSA Rewards
2. Pro-cell Announces a Knock at the Door of Emerging Markets
3. March of Dimes Announces Nursing Scholarship Recipients
4. The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps in Public Awareness of Gout
5. AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR
6. Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes
7. QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
8. Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders
9. Secretary Shinseki Announces $215 Million in Projects for Rural Veterans
10. Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades
11. Medstrat Announces Integration of Echoes With MacPractices EMR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology: